Established Icon

About Us

About us

Our Story

Founded in 1988 by the Late Dr. Muhammed Majeed, an internationally acclaimed scientist and entrepreneur in the area of “Evidence Based Medicine”, Sabinsa is a research-driven multinational health science company. We are leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, and biotics for the nutritional, cosmetic, pharmaceutical and food industries.

Sabinsa has carved a niche for itself by its extensive research support for its customers and products, and the scientific credentials of its technical staff.

Sabinsa’s efforts have begun to earn the company vast recognition, in addition to growing sales.

Mission & Vision

We envision a world where nature-inspired wellness is accessible through trusted, ethically sourced ingredients and cuttingedge research. Sabinsa is committed to innovation through research, ensuring our products are safe, effective, and backed by clinical studies–bridging tradition with science.

The company has pioneered sustainable practices with its farmers and implemented solar capabilities at some of its centers to become a global leader in nutraceuticals and cosmeceuticals markets by providing science-based solutions that empower healthier lives.

Our Milestones

Our Legacy of Progress and Innovation

2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1998
1997
1996
1993 – 95
1991
1988
2022

2022

  • Sami-Sabinsa Group Releases Book on “Selenium in Health and Diseases”
  • Sami-Sabinsa honoured with “Best Manufacturer Export Award 2022” by FKCCI
  • Sami-Sabinsa Group has been ranked as one of the Top 10 Pharma Laboratories in the year 2022 by India Pharma Outlook
  • Dr. Muhammed Majeed, Chairman and Founder of Sami-Sabinsa Group, was named the “Legend of the Millennium in Nutraceutical Industry” by ASSOCHAM for his outstanding contributions to the field of nutraceuticals.
  • In conjunction with the Global Ayush Investment & Innovation Summit 2022, Sami-Sabinsa signed a MoU with the farmers of J&K through the J&K Medicinal Plants Board.
  • Sami-Sabinsa Group signed a historic MoU with Manav Sadhan Vikas Sanstha (MSVS) for the cultivation of Garcinia indica plant used for the production of Livinol®.
  • Sami-Sabinsa Group attended the Joint Parliamentary Committee meeting on the Biological Diversity (Amendment) Bill, 2021 to discuss the impact of the amendment on the Nutraceutical Industry and possible ways forward.
  • Sabinsa has received Novel Food approval from the European Food Safety Authority (EFSA) for its patented Curcumin C3 Reduct®.
  • Sabinsa receives TGA Approval for use of LactoSpore® as listed medicine in Australia.
  • Sami-Sabinsa accomplishes Intellectual Property Milestone with over 400 plus Granted Patents (as of Dec 2022)
  • Sabinsa’s Cirpusins® shows effective management of obesity and lipid levels in a published study.
  • Indian Customs grants Sami-Sabinsa Group the Authorized Economic Operator (AEO) Tier–Two Certificate.
  • To support various CSR initiatives, Dr. Majeed Foundation contributed Rs. 4.88 Crores during the Financial Year 2021-2022.
2020

2020

2019

2019

2018

2018

2016

2016

2015

2015

2014

2014

  • Sabinsa adds four new patents, bringing world wide portfolio to 91
  • C3 Reduct® wins Functional Ingredients editors choice award for best science
  • Sami and Sabinsa receive Best New Product Excellence Award in the raw material category at Panacea-Natural roduct Expo India for Saberry®
  • Sabinsa / Sami Labs entered into a Memorandum of Understanding with India’s Ayurvedic research organization, Arya Vaidya Sala, Kottakkal (AVS)
  • Sabinsa / Sami Labs receives two pharmexcil awards for 2012 – 2013 in the herbals, ayurveda & nutraceuticals category: The gold award for patents and the silver award for exports in herbals
  • Former President of India visits Sami Labs (late A.P.J. Abdul Kalam)
  • Sabinsa introduces new form of coleus with ForsLean® Soft Extract
  • Study shows Boswellia® cream may provide relief for psoriasis
  • Sabinsa initiates lawsuit against four companies for Curcumin C3 Complex® patent infringement
  • Iranian clinical study shows combination of C3 Complex® and BioPerine® offer relief for osteoarthritis patients
  • Sabinsa Launches Animal Nutrition Division: Vetvitals®
  • Sabinsa’s Curcumin C3 Complex® and BioPerine® combination used in metabolic syndrome study
  • Sabinsa/Sami Labs acquires KCP Biotech, expands capacity and adds more colors
  • Sabinsa teams up with Fruit D’Or to launch LactoSpore®-Cranberry combination LactoCran™
  • Sabinsa’s LactoSpore® moves into cosmeceuticals with topical Candida products
2013

2013

2012

2012

2010

2010

  • Sami's Kunigal plant near Bangalore, India received NSF (National Sanitation Foundation) GMP certification
  • Received the first patent in China for "Process For Preparing Water Soluble Diterpenes And Their Applications"
  • Sami Labs inks an agreement with CIPLA to market its drug, Sornip for Psoriasis in Indian market
  • Sami's Kunigal plant near Bangalore, India received Bureau Veritas ISO 22000 Certification
2009

2009

  • Sabinsa received the 2009 Herbal Industry Leader Award from the American Herbal Products Association
  • Sabinsa received its 57th patent and it is the first patent from Russia
2008

2008

  • NABL accreditation for laboratories of Sami Labs Limited
  • Continuous Extraction plant commissioned by Sami Labs Limited in Bangalore
2007

2007

  • Sabinsa sets up its office in South Africa
2006

2006

  • Forskolin Eye Drops approved by DCGI for Glaucoma
  • Sabinsa Europe GmBH was set up in Langen, near Frankfurt in Germany
2005

2005

  • Received two patents for Tetrahydropiperine
  • Received the second Thomas Alva Edison Patent Award for 2005
2004

2004

  • Sabinsa's US Patent for ForsLean® received the Thomas Alva Edison Patent Award for 2004
  • Dr. Majeed was conferred the Ellis Island Medal of Honor by the National Ethnic Coalition of Organizations (NECO)
2003

2003

  • MGP Herbal (P) Ltd was acquired to facilitate and co-ordinate Herbal Cultivation - a major step that helped provide jobs to several farmers in India
2002

2002

  • Super-Critical Fluid Extraction facility set up at Nelamangala
  • The R & D Centre of Sami Labs Limited, Bangalore received the DSIR Award for its R & D efforts
2001

2001

  • The anti-obesity product Forslean® was voted as the Best New Product of the year by Nutraceutical Industry Association – Nutracon in the US
  • Sabinsa received its first European patent on Curcuminoids
  • Sabinsa Japan Corporation was started
2000

2000

  • Biotechnology Center established at Nelamangala, Bangalore
  • Tetrahydrocurcuminoids, also referred to as “White Curcumin” was introduced as a skin lightener into the US market
1998

1998

  • Sami Chemicals and Extract Pvt. Ltd. – name was changed to Sami Labs Limited to reflect more accurately its current activities
1997

1997

  • New Jersey Technology Fast 50 Award
  • Sabinsa listed again in the Inc 500 companies, ranking # 90
  • Award for Export Performance for Spice products from President of India
1996

1996

  • Sabinsa was listed in the Inc 500 companies, ranking # 70
  • First US patent awarded for the product BioPerine® was awarded to Sabinsa Corporation
  • An Export-Oriented manufacturing unit is established at Kunigal, Bangalore
1993 – 95

1993 – 95

  • Standardization of Indian herbal medicines by Sami research group
  • Sabinsa started the “Sabinsa on Wheels” program also know as SOW. Here the Sabinsa team endeavors to share its knowledge to a large group of professionals and common man on its diverse range of products
1991

1991

  • Sami Chemicals and Extracts Pvt Ltd set up in Bangalore
1988

1988

  • Sabinsa Corporation, New Jersey USA was setup

What We Do

Sabinsa, a pioneer and global leader in health science, is a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, biotics, and enzymes.

The company’s corporate R&D encompasses independent research divisions, including Natural Drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology, and Formulation R&D. These divisions collaborate in a synergistic work model to produce products that adhere to international standards.

With the collective wisdom of over 120 research scientists, Sami-Sabinsa Group has developed standardized natural extracts that render alternative therapy to emerging nutritional and health requirements across the globe

Manufacturing Facilities

Sami-Sabinsa Group manufactures its products utilizing global standards global standard at its state-of-the-art manufacturing facilities located in Bengaluru, Hyderabad (India), and Utah (USA).

This facility is designed and equipped with fermentation tanks to produce probiotics and enzyme blends.

A unique facility with a continuous extractor made entirely of Stainless Steel 316, more than 40 tonnes of herbal raw material can be extracted in a day.

A recent addition to our several manufacturing facilities, it has the capability to process and manufacture multiple products of both synthetic and natural origin.

One of the major manufacturing facilities of the group is situated here. With well developed and segregated blocks, this facility has the capability to process several tonnes of extract and manufacture multiple products of both synthetic and natural origin.

This facility at Utah provides a strong formulation support and is equipped to handle various dosage forms. The stick pack facility offers convenient package form for the growing industry needs.

The state-of-the-art greenfield facility has adopted the best-in-class technologies for the manufacture of Synthetic Active Nutraceutical Ingredients (ANI) and Active Pharmaceutical Ingredients (API) for the global market.

This facility is the first of its kind wherein the Industry and Academia have collaborated to develop it commercially.

A state-of-the-art facility that adapts a new technology, wherein carbon dioxide is used as the extraction solvent. As eco-friendly technology, it provides both the manufacturer and the end user a clean extract with an almost intact bio-potency.

Intellectual Properties

Sabinsa has a strong intellectual property portfolio and has received over 510 global patents with 290 more pending worldwide.

Number of Patents

510+

Total Number of Patents

Number of Patents

26+

Total Number of Countries

Number of Patents

120+

Total Number of Products

Recognitions

Since its inception Sabinsa has been consistently honored throughout the years with numerous accolades and awards for its science and technological advancements within the nutrition, cosmetics, and pharmaceuticals industries.

Possibilities Background

Explore endless possibilities with us.
Let’s connect and make it happen!

Get In Touch